Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Notable Labs (NTBL)
NASDAQ:NTBL
Notable Labs (NTBL) Stock Price & Analysis
733 Followers
NTBL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.83 - $11.23
Previous Close$1.02
Volume29.72K
Average Volume (3M)400.76K
Market Cap
$9.20M
Enterprise Value-$577.37K
Total Cash (Recent Filing)$11.82M
Total Debt (Recent Filing)$2.05M
Price to Earnings (P/E)-4.9
Beta1.36
Next Earnings
Aug 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding9,018,261
10 Day Avg. Volume2,026,183
30 Day Avg. Volume400,762
Standard Deviation0.24
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.61
Price to Sales (P/S)29.67
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.86
Enterprise Value/Gross Profit-5.11
Enterprise Value/Ebitda0.17
Forecast
1Y Price Target
$7.00Price Target Upside586.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Notable Labs News
PremiumCompany Announcements
Notable Labs Shares Strategic Insights in Business Overview
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressNotable Labs is advancing volasertib into a phase II clinical trial for relapsed/refractory AML patients, showing commitment to developing treatments for hard-to-treat cancers.
Financial StabilityWith current cash reserves expected to fund operations well into the following year, Notable Labs demonstrates a strong financial position to support its research and development efforts.
Innovative TechnologyThe company's PPMP platform has proven its ability to predict non-responses in patient treatments, marking a significant step forward in personalized medicine for leukemia care.
Bears Say
Drug EfficacyThe lack of efficacy in all patients treated with Fosciclopirox raises questions about the predictive capabilities of the PPMP platform.
Financial PerformanceCash burn from operations during the quarter was -$3.6 mm.
Stock ValuationLower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last quarter.
---
Ownership Overview
76.96% Insiders
0.01% Mutual Funds
2.27% Other Institutional Investors
20.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NTBL FAQ
What was Notable Labs’s price range in the past 12 months?
Notable Labs lowest stock price was $0.83 and its highest was $11.23 in the past 12 months.
What is Notable Labs’s market cap?
Currently, no data Available
When is Notable Labs’s upcoming earnings report date?
Notable Labs’s upcoming earnings report date is Aug 12, 2024 which is in 83 days.
How were Notable Labs’s earnings last quarter?
Currently, no data Available
Is Notable Labs overvalued?
According to Wall Street analysts Notable Labs’s price is currently Undervalued.
Does Notable Labs pay dividends?
Notable Labs does not currently pay dividends.
What is Notable Labs’s EPS estimate?
Notable Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Notable Labs have?
Notable Labs has 9,018,261 shares outstanding.
What happened to Notable Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Notable Labs?
Among the largest hedge funds holding Notable Labs’s share is ARK Investment Management LLC. It holds Notable Labs’s shares valued at N/A.
---
Notable Labs Stock Smart Score
Company Description
Notable Labs
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
---
NTBL Stock 12 Month Forecast
Average Price Target
$7.00
▲(586.27% Upside)
Technical Analysis
Best Analysts Covering NTBL
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-39.67%
reiterated a buy rating last month
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.67% per trade.
---